Compare LyondellBasell Industries NV (LYB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Mesoblast Limited — how do they compare? LyondellBasell Industries NV trades at $60.34 (market cap $18.89B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: LyondellBasell Industries NV is far larger — about 10.4× Mesoblast Limited's market cap, and LyondellBasell Industries NV pays a 4.72% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Mesoblast Limited for 14 Days on average.
| LYB | MESO | |
|---|---|---|
Market Cap | $18.89B | $1.81B |
Volume | 2,621,859 | 240,620 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $20.96 |
52-Week Low | $42.28 | $13.19 |
Typical Hold Time | 87 Days | 14 Days |
Enterprise Value | $30.48B | $1.89B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $60.36, up 2.42% today, with a bearish technical signal but mixed fundamental outlook. Revenue declined to $30.15B in 2025, resulting in a net loss of $745M, though recent quarters show earnings beats. The stock is supported by a 45% analyst buy rating and a $69.38 consensus price target, but faces headwinds from cyclical chemical demand and high debt levels.
LYB offers potential upside from operational recovery and dividend yield, but risks include volatile earnings, margin pressure, and industry competition. The stock remains a speculative play on chemical sector stabilization, with investor sentiment divided between near-term challenges and long-term value.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
